FOLD AMICUS THERAPEUTICS, INC.
FY2025 10-K
AMICUS THERAPEUTICS, INC. (FOLD) filed its fiscal year 2025 10-K annual report with the SEC on Feb 20, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Global biotechnology company focused on developing transformative rare disease medicines including Fabry and Pompe disease therapies
- • New emphasis: Licensed exclusive U.S. commercialization rights to Phase 3 FSGS drug candidate DMX-200 in April 2025
Management Discussion & Analysis
- • Revenue $634.2M, up $105.9M YoY from $528.3M driven by Galafold and Pombiliti+Opfolda growth plus $13.5M currency impact
- • Gross profit $561.3M vs $475.4M; cost of goods sold $72.9M vs $52.9M; operating loss narrowed with net loss $27.1M vs $56.1M
Risk Factors
- • Regulatory risk: Pending merger requires Hart-Scott-Rodino Act antitrust approval and clearance from EU and Japanese authorities, risking delays or termination
- • Geopolitical risk: Transaction contingent on foreign direct investment approvals in European and Japanese markets, exposing reliance on international regulatory outcomes
Financial SummaryXBRL
Revenue
$634M
Net Income
-$27M
Gross Margin
88.5%
Operating Margin
5.2%
Net Margin
-4.3%
ROE
-9.9%
Total Assets
$950M
EPS (Diluted)
$-0.09
Operating Cash Flow
$33M
Source: XBRL data from AMICUS THERAPEUTICS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on AMICUS THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.